BioCryst’s Orladeyo Surpasses Expectations: A Strong Buy Recommendation

BioCryst (BCRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stacy Ku from TD Cowen maintained a Buy rating on the stock and has a $20.00 price target.

Stacy Ku has given her Buy rating due to a combination of factors including BioCryst’s strong performance with Orladeyo, which has exceeded sales expectations. The company reported $134 million in sales for the first quarter, surpassing consensus estimates by over $10 million. This growth is attributed to effective management strategies that have improved patient transitions to paid drug, leading to a significant increase in sales.
Additionally, the company has raised its guidance for Orladeyo’s full-year sales to between $580 million and $600 million, reflecting steady patient accumulation and retention. Despite concerns about the competitive landscape, Stacy Ku believes that Orladeyo will continue to dominate the oral segment for HAE prophylaxis and is on track to become a billion-dollar product. The long-term retention rate of over 60% further supports the company’s solid patient foundation, making the stock an attractive investment opportunity.

In another report released on April 28, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $20.00 price target.